On March 5, 2024, Michael Stubblefield, Avantor’s President and Chief Executive Officer, attended a healthcare industry conference at which he was asked questions about Avantor’s competitive position in its Laboratory Solutions business. In response, Stubblefield emphasized that Avantor’s competitive position was “strong” and that the company had “confidence in the positioning” due to its investments in digital capabilities, which would “make it more efficient for our customers to engage with us.” Throughout the Class Period, Avantor’s management continued to represent that the company had a strong competitive position within its industry.
Then, on August 1, 2025, Avantor shocked the market when it reported disappointing second quarter 2025 financial results, including net sales of $1.122 billion (a year-over-year decrease of 3%) and Adjusted Operating Income of $133.3 million (a year-over-year decrease of 11.7%) in Avantor’s Laboratory Solutions business. During the accompanying earnings call that day, Avantor also further reduced the company’s full-year guidance, including its guidance for growth in Laboratory Solutions (now projecting growth of “minus low single digits,” down from minus low single digits to flat). Avantor attributed the weakening outlook for the company’s Laboratory Solutions business to “increased competitive intensity.”
On this news, the price of Avantor common stock declined $2.08 per share, or more than 15%, from a close of $13.44 per share on July 31, 2025, to close at $11.36 per share on August 1, 2025.
Please contact us today if you purchased shares of Avantor common stock between March 5, 2024 and July 31, 2025. You can fill out our online form below, call us at 484-270-1453, or email us at info@ktmc.com.